Introduction
Spondyloarthritis (SpA) is a heterogeneous group of conditions composed of inflammatory axial and peripheral arthritis, uveitis, inflammatory bowel disease, psoriasis, dactylitis, and enthesitis [1] . Psoriatic arthritis affects 0.1-1.0 % of the general population [2, 3] , while the prevalence of ankylosing spondylitis is likely very close to 1 % [3] . SpA was previously only treated with non-steroidal anti-inflammatory drugs (NSAIDs) and traditional disease-modifying anti-rheumatic drugs (DMARDs), with varying success. The advent of TNF inhibitors heralded enormous success with treatment of both radiographic and non-radiographic spondylitis. Availability of novel IL-17 axis inhibitors has opened more treatment options for these diseases. The focus of this review will be on the differential adverse events among the TNF-α-inhibiting and IL-17-modulating classes of agents.
TNF-α Inhibitors
Pro-inflammatory cytokines such as tumor TNF-α play a central role in the inflammation underlying SpA, and agents that selectively block TNF-α have proved highly effective in treating PsA and ankylosing spondylitis (AS). They work by blocking the cytokine itself (infliximab, adalimumab, and golimumab) or its antigen-binding fragment (Fab′) (certolizumab), or its receptor (etanercept), and prevent the activation and expansion of T cells, leading to a decrease in overall inflammation.
Since TNF-α is a pro-immune cytokine involved in antimicrobial type 1 immunity, patients treated with TNF-α antagonists have increased risk of infections [4•, 5, 6] , and a large majority of these are upper respiratory tract infections [7• ]. An increased risk of opportunistic infections, particularly fungal infections and tuberculosis, is noted as a black box warning with these agents. In addition, rates of demyelinating disorders, lymphomas, and solid tumors have been noted to be increased in populations using these medications [6] . Availability of TNF-α inhibitors on the commercial market for a prolonged period of time has provided information about long-term safety from post-marketing surveillance, registries, long-term follow-up studies, and voluntary reporting [4•, 7••, [8] [9] [10] . Table 1 outlines side effects, malignancies, opportunistic infections, and deaths for each drug included in this review.
Infections
The most common (95 % in study patients) non-serious adverse event (AE) for all TNF-α antagonists is infections. After nearly 3 years of follow-up, the most common AE in the adalimumab trial in PsA patients were similar to those in the first 6 months of the study: upper respiratory tract infections, nasopharyngitis, and sinusitis were seen in 21.5, 17.4, and 10.7 %, respectively [8] . Similar AE were seen in AS patients in the ATLAS trial over a period of 2 years [9] . A metaanalysis of randomized placebo-controlled trials of TNF-α inhibitors in patients with psoriasis and PsA patients indicates an odds ratio (OR) of 1.09 (95 % [29] 1 case active TB [67] None reported 2 deaths (1 from MI and another of unknown cause; both deemed unrelated to study drug) [22] There is enormous data available about the use of TNF inhibitors in RA, and the findings of the longer-term data are generally consistent with those of shortterm trials. In the Italian GISEA registry which includes 2769 RA patients on long-term anti-TNF therapies, the overall incidence of serious infections was 31.8 events per 1000 patient-years of follow-up (95 % CI 25.2-38.3); this risk was numerically higher during the first year of treatment compared to the second year, but it was not statistically significant (p=0.8) [10] . This incidence was similar to the prior German data from the RABBIT registry [11] . In the GISEA registry, multivariate analysis showed that steroid is a significant predictor of infection in TNF-inhibitor use, OR 1.633 (95 % CI 1.01-2.644) [10] . In univariate analysis, advanced age at initiation of TNF-inhibitor therapy is associated with risk of serious infection (pG0.0001) [10] .
Tuberculosis and Opportunistic Infections
TNF-α inhibitor therapy is associated with an increased risk of granulomatous infection, most notably reactivation of tuberculosis (TB). In latent tuberculosis infection (LTBI), few mycobacteria are housed in a granuloma; introduction of the TNF antagonist upsets this barrier and allows mycobacteria to reactivate and progress to active TB infection [12] . Prophylactic treatment has lowered this risk to reactivation [12] .
Because studies of individual TNF inhibitors differ in details of study design, it has been difficult to discern differences in reactive TB rates among each discrete agent. However, it appears monoclonal antibodies to TNF carry a higher risk of reactivating latent TB. One US study demonstrated that infliximab has a higher rate of TB compared to etanercept (54 and 28 per 100,000 treated patients for infliximab and etanercept, respectively) [13] . Based on the French Research Axed on Tolerance of bIOtherapies (RATIO) registry, which includes patients with a variety of inflammatory and autoimmune diseases on biologic therapies, 69 cases of TB were reported over a total of 57,711 patient-years; these cases were related to infliximab and adalimumab use, but none of them had received the currently recommended chemo-prophylactic treatment for latent TB [14] . The British Society for Rheumatology Biologics Register (BSRBR) confirmed similar results in a cohort of 10,712 patients over median 3.2 years, finding a 3-to 4-found higher rate of TB in RA patients on infliximab and adalimumab compared to etanercept [15] .
The RATIO registry also has found that infliximab and adalimumab carry a higher risk of a variety of serious non-tuberculous opportunistic infections compared to etanercept [16] . The same registry found a significantly higher risk of herpes zoster infection with monoclonal antibodies to TNF (adalimumab and infliximab) compared to the soluble TNF-α receptor, odds ratio (OR) 3.49 (95 % CI 1.12-10.90, p=0.0316) [17] . A similar trend was seen in the same registry regarding Legionella pneumophila infection; the standardized incidence ratio (SIR) for all TNF inhibitors was 13.1 compared to the general French population.
However, the SIR for infliximab and adalimumab were higher, 15.3 and 31.8, respectively, in comparison to etanercept, SIR 2.4 [18] .
As such, pre-screening for tuberculosis, prophylaxis in appropriate candidates as well as consideration of zoster vaccine, and continued surveillance remain imperative in SpA patients being considered for TNF-blocker therapy.
Malignancy
As TNF has been implicated in the pathogenesis of malignancy [6] , there has been a concern for increased risk of malignancy with TNF-α inhibitor use in all autoimmune diseases. Including patients with all indications for the drug, the rate of lymphomas has been noted in adalimumab to be 0.1/100 patient-years and the rate of non-melanomatous skin cancer to be 0.2/100 patient-years [19•] . The French RATIO registry observed a discrepancy among agents; in a series of 38 cases of lymphoma in patients with a variety of autoimmune diseases on anti-TNF therapy, a significant risk was found to be related to infliximab or adalimumab use versus etanercept, OR 4.12 (95 % CI 1.36-12.49) and OR 4.73 (95 % CI 1.27-17.65), respectively [20] .
Unfortunately, this relationship remains unclear as conflicting data abound. In the psoriasis literature, it is reported that the risk of lymphoma as a result of TNF-antagonist therapy is approximately equivalent to the lifetime risk without TNF-blocker therapy [4•]. One long-term use report indicates that the observed number of malignancies in AS and PsA were similar to the number expected for age-and sex-matched populations [19•] . In a meta-analysis of TNF-blocker use in psoriasis and PsA patients, the OR for malignancy was not significant: 1.48 (95 % CI 0.71, 3.09) [7••] . In this meta-analysis of 20 trials which included studies of each of the five TNF antagonists, more than 70 % of the 28 malignancies noted in the trials were non-melanomatous skin cancers [7••] . Over 10 years, in one Belgian population, the incidence of malignancy after one or more anti-TNF therapies for SpA was noted to be 500.1 per 100,000 patient years, higher than the general population [21] . However, it is noted that this controversial relationship stems from the concern that some increased risk may be disease related and not treatment related.
Laboratory Abnormalities
Laboratory abnormalities including transaminitis, bilirubinemia, and mild creatinine kinase elevations (CPK) have been noted with TNF inhibitors. Transient elevation of liver enzymes was seen with adalimumab [8] , certolizumab [22] , and golimumab [23] . Similarly, in the golimumab study of PsA patients, Kavanaugh et al. noted hyperbilirubinemia in study patients [24] . In the AS trial of certolizumab, 5.1 % of patients receiving the study agent had increased blood CPK. This was noted to be transient and resolved with continued therapy [24] . Cytopenias have been reported in TNF-inhibitor trials, including thrombocytopenia, lymphocytopenia, and neutropenia [25, 26] . These cytopenias are generally mild and transient. [27] has been noted to be effective.
Skin Reactions and Extra-Articular Features
There are concerns of new or worsening extra-articular features, including inflammatory eye disease in patients. In the etanercept trial for AS patients, several cases of uveitis/iritis (some with prior history, others with new diagnosis) as well as de novo colitis and psoriasis were reported [25] . In the study comparing adalimumab, infliximab, and etanercept in the treatment of uveitis in SpA patients, etanercept did not decrease the rate of uveitis flares in patients with at least one prior flare; the monoclonal anti-TNF antibodies did decrease the rate of uveitis flares [28] . There were five cases of new uveitis documented in the certolizumab study in AS patients [29] . However, there is a case of successful treatment of refractory SpA in a patient with uveitis with certolizumab [30] .
Inflammatory Bowel Disease
Monoclonal antibodies to TNF-α and pegylated Fab′ portion are approved for treatment of one or both inflammatory bowel diseases. Etanercept, however, failed to show efficacy in Crohn's disease [31] . There is ample evidence that shows that IL-17 is highly upregulated at sites of inflamed tissues of inflammatory and autoimmune diseases and that it amplifies the inflammation through synergy with other cytokines, such as TNF-α [34] . IL-17A-producing mast cells and neutrophils are demonstrated in abundance in psoriatic plaque compared to normal skin, as well as in inflamed synovial tissue in AS patients [33•] .
IL-17
More recently, interleukin-12 (IL-12) and interleukin-23 (IL-23), cytokines that help drive an adaptive immune response by inducing naïve CD4+ lymphocytes to differentiate into Th1 cells and Th17 cells, have been identified as key mediators of inflammation in PsA and AS [35] . Novel approaches in the treatment of PsA and SpA involve blockade of the IL-17 axis by using a new class of biologics.
Ustekinumab is a monoclonal antibody that binds to the common p40 subunit of IL-12/IL-23, affecting both the Th1 and Th17 pathways [33•, 36 ••]. It is approved for the treatment of adult patients with moderate to severe plaque psoriasis, and for active PsA, alone or in combination with methotrexate. Efficacy and safety of ustekinumab compared to placebo in 186 patients with PsA who had spondylitis and peripheral joint involvement have also been recently reported in an abstract [37] . Data from 108 weeks trial showed that the proportion of patients with AEs were comparable between the placebo and combined ustekinumab-treated groups (AEs 32.9 vs 24.1 %; serious adverse events (SAEs) 1.4 vs 0.9 %; discontinuations due to AEs 2.9 vs 0.9 %; serious infections 14.3 vs 7.8 %). Through 2 years, safety observations were consistent with the overall PsA population.
More direct inhibitors, secukinumab and ixekizumab, are both monoclonal antibodies directed against IL-17A. Secukinumab has just been approved by FDA for the treatment of moderate to severe plaque psoriasis in adult patients, and the recently reported phase III studies show its effectiveness in PsA as well [38, 39] . Most importantly, it provided a significant and sustained inhibition of joint structural damage in active psoriatic arthritis, regardless of prior TNF inhibitors or concomitant methotrexate [39] .
Brodalumab is a human anti-IL-17 receptor A (IL-17RA) monoclonal antibody. Data from an open-label extension of a phase 2 study in adult patients with active PsA suggest that brodalumab is also a promising new biologic for patients with PsA [40] . Adverse effects were similar in brodalumab and placebo groups. These innovative treatment options have demonstrated improved clinical outcomes in both diseases. Although phase III trials are underway for these novel therapeutics in AS and PsA, some conclusions might be drawn from initial trials and bring light to comparing adverse effects to those of tumor necrosis factor inhibitors.
Infections
As IL-17 cytokine functions as part of the Th17 defense against extracellular pathogens, it is foreseeable to expect some increased risk of infections in patients on IL-17 blocker therapy. In the ERASURE (Efficacy of Response and Safety of Two Fixed Secukinumab Regimens in Psoriasis) trial, there were higher proportions of patients with infections and infestations in the secukinumab groups (29.4 % in the 300-mg group and 26.9 % in the 150-mg group) than in the placebo group (16.2 %) during the induction period [36••] . The most common adverse events in the induction period and the entire treatment period in this study were nasopharyngitis, headache, and upper respiratory tract infection.
In pooled long-term safety data [41, 42] from the randomised, double-blind, placebo-controlled trial of ustekinumab in psoriasis patients [43, 44] , which included patients on ustekinumab for as long as 3 years, rates of adverse events were low and comparable among all groups (1.2 to 1.9 %). No dose response in rates of AEs, overall infections, or SAEs was apparent through 3 years. Serious infections were listed as the most common serious adverse event with ustekinumab, a rate of 0.6 events per 100 patient-years in the 45-mg-dose group, and a rate of 1.4 events per 100 patient-years in the 90-mg-dose group. Rates of AEs, infections, SAEs, and AEs leading to study agent discontinuation remained generally stable or decreased over time. Pooled data from four clinical trials of ustekinumab in psoriasis patients were reviewed including 9000patient-years of follow-up in 3117 patients treated for up to 5 years [45•] . Most observed AEs were non-serious and did not result in treatment discontinuation, and no clear signals of dose response or effects of cumulative exposure on safety outcomes were observed. These results confirm that the long-term safety profile of ustekinumab continues to be favorable and consistent with previous reports at 3 years follow-up [45•] . The difference initially observed in the incidence of serious infections between the 45-and 90-mg groups after up to 3 years of treatment continued to narrow with two additional years of follow-up, suggesting little difference in infection risk between the two doses. This infection rate was not elevated when compared to psoriasis patients on standard agents [42] .
Similarly, during the brodalumab trial in PsA, the most frequent adverse events reported were respiratory infections (nasopharyngitis, upper respiratory tract infection (URTI), bronchitis, sinusitis) [46, 47] . During the blinded phase, the URTI rate was reported in 12 % of brodalumab patients compared to 7 % of placebo patients [46] . Likewise, in the secukinumab trial in AS, respiratory infection was one of the most common AE reported (29 % in study patients); the incidence of infections was higher in the secukinumab group compared to the placebo [48] .
Tuberculosis and Opportunistic Infections
At this time, both short-and long-term trials have not reported any tuberculosis or opportunistic infections in the IL-17 axis inhibitors. No reactivation of latent tuberculosis or viral hepatitis was observed in any psoriasis trial with ustekinumab [49] .
Across five clinical trials of ustekinumab-treated patients with psoriasis, there were no atypical mycobacterial diseases, disseminated salmonellosis, or systemic fungal infections observed in ustekinumab-treated patients. In addition, no opportunistic infections were reported, except two previously reported cases of severe cutaneous herpes zoster infection with no evidence of visceral involvement [50] . The association of active tuberculosis and latent tuberculosis infection reactivation with some anti-TNF agents was not observed in these analyses. The possible pathophysiological explanation for this observation may be that during long-term use of ustekinumab treatment, IL-12/23 inhibition is possibly incomplete and does not compromise host defense towards these pathogens.
Also, no cases of LTBI reactivation were observed in patients receiving concomitant INH prophylaxis for LTBI. INH prophylaxis was generally well tolerated by these patients with psoriasis [51] .
Major Adverse Cardiovascular Events
The second most frequent serious AE in the pooled ustekinumab data in psoriasis patient trials was cardiac disease; the rate was 0.8 events per 100 patient-years in the 45-mg-dose group and 1.3 events per 100 patient-years in the 90-mg-dose group [41, 42] . In a systematic review and meta-analysis in psoriatic patients who had received IL-12/23 inhibitors (ustekinumab or briakinumab), a higher risk of major adverse cardiovascular events (MACE) [including cardiovascular death, myocardial infarction, or stroke] was noted compared to those with placebo: OR 4.23 (95 % CI 1.07-16.75, p=0.04) [52] . However, this risk has not been seen with secukinumab when compared with placebo or etanercept. MACE have been reported for a similar proportion of patients on secukinumab and etanercept: 0.4 % with 300 mg, 0.4 % with 150 mg, and 0.3 % for etanercept.
Malignancy
A handful of solid and skin cancers have been reported in the short time the IL-17 axis inhibitors have been studied; non-melanomatous skin cancers (NMSCs) were the most commonly observed malignancy. In the pooled ustekinumab data in psoriasis patients, non-melanomatous malignancies occurred at a rate of 0.7 events per 100 patient-years in the 45-mg-dose group and a rate of 0.5 events per 100 patient-years in the 90-mg-dose group [41, 42] . At 3 years follow-up, this malignancy rate was similar to that in the general American population; the standardized incidence ratio was 1.05 (95 % CI 0.69-1.53) [42] . In pooled psoriasis data from the PHOENIX 2 trial, over 5 years of follow-up, 0.66 malignancies (excluding NMSCs) were reported per 100 subject years of follow-up; 0.28 non-melanomatous skin cancers per 100 subject years of follow-up were reported [53] .
Across the clinical trials of ustekinumab in psoriasis, the spectrum of malignancies observed was consistent with that expected in the general population. The incidence of malignancies other than NMSCs in ustekinumab-treated patients exposed up to 3 years was 0.60/100 patient-years [49] . This is consistent with that expected in the general US population [42] . Overall, the incidence of NMSCs in ustekinumab-treated patients is 0.52/100 patient-years [49] .
The breast and skin cancers noted in the ustekinumab trial [54•] were found in patients with prior TNF-inhibitor exposure; similarly, there is one report of a basal cell cancer in a patient receiving ustekinumab for PsA, though it was unclear if this patient had received TNF-I previously [55] . It was not clear in the brodalumab trials whether the metastatic lung, breast, and skin cancer cases (one each) had received previous TNF-inhibitor treatment [46, 47] .
Laboratory Abnormalities
Several reports of cytopenias have been noted in the IL-17 axis blocker trials. In the brodalumab study in PsA patients, there were four reports of grade 1 neutropenia (one in the 140-mg group, three in the 280-mg group) seen during the first 12 weeks, but none seen in the open-label 9-month extension of the trial [46] . In the secukinumab trial in PsA, grade 1 neutropenia was observed in five secukinumab patients and grade 2 in one patient [56•] . Similarly, several cases of grade 1 leukopenia and neutropenia were reported in AS patients receiving secukinumab, but the exact number of cases was not noted [48] . Recent studies have established an important role of Th17 cells, the manufacturers of IL-17, in the pathogenesis of acute myeloid leukemia [57, 58] ; it is possible that when a mechanism along these lines is blocked, such cytopenias are resultant.
Skin Reactions
Injection site erythema or injection site reactions have been noted in small numbers in both brodalumab and ustekinumab studies (2-4 % [46, 47] and 0-4 % [55, 59], respectively). New inflammatory arthritis was noted in two patients in a study of ustekinumab in psoriasis patients [60] .
Inflammatory Bowel Disease
Secukinumab pooled data from the psoriasis trials has shown a very low risk of incident inflammatory bowel disease as well as exacerbation of prevalent inflammatory bowel disease. When compared to the etanercept-exposed psoriatic patients in the same pooled analysis, there was similar exposure-adjusted incidence of inflammatory bowel disease (0.35/100 patient-year incidence rate (IR) (95 % CI 0.10-0.90) for all exposed to the 150-mg dose; 0.26 IR (95 % CI 0.05-0.75) for the 300-mg dose; 0.34 IR (95 % CI 0.01-1.90) for the etanercept comparison group). These low rates are results of three reported cases of Crohn's, two existing cases with exacerbations, and one incident case with baseline symptoms suggesting possible undiagnosed inflammatory bowel disease. However, the FDA label for secukinumab cautions use in patients with known inflammatory bowel disease as well as monitoring for potential new bowel disease symptoms in other patients [61] . In the brodalumab trial, the presence of IBD was an exclusion criterion for entry to the study [46] .
Head-to-Head Safety Comparison Between TNF-α Inhibitors and IL-17 Axis Inhibitors
The ACCEPT trial is a short clinical trial that provided comparative safety between ustekinumab to etanercept in the treatment of patients with plaque psoriasis; however, this trial only lasted for 12 weeks [62••] . Infection rates were similar between the ustekinumab (45-and 90-mg doses) and etanercept groups, occurring in 29.1, 30.6, and 29.7 % of patients. Adverse events of any kind were experienced by 70.0, 66.0, and 69.2 % of patients. Mild injection site reactions were more common in the etanercept group-24.8 versus 4.3 and 3.7 % in the ustekinumab group.
Another randomized, phase 3 trial, FIXTURE (Full Year Investigative Examination of Secukinumab vs. Etanercept Using Two Dosing Regimens to Determine Efficacy in Psoriasis), assessed the efficacy and safety of secukinumab, at a dose of 300 or 150 mg, compared to etanercept in patients with plaque psoriasis [36••] . The incidences of adverse events between the secukinumab and etanercept groups in the FIXTURE study during the entire 52-week treatment period were similar. The rates of serious adverse events were 6.8 events per 100 patient-years in the 300-mg secukinumab group, 6.0 events per 100 patient-years in the 150-mg secukinumab group, 7.0 events per 100 patient-years in the etanercept group, and 8.3 events per 100 patient-years in the placebo group. Infection rates were 26.7 % with the 300-mg dose of secukinumab, 30.9 % with the 150-mg dose of secukinumab, 24.5 % with etanercept, and 19.3 % with the placebo. Candida infections were more common with secukinumab (4.7 and 2.3 % among the two doses) than with etanercept during the entire treatment period.
The incidence of injection site reactions during the entire study was lower in the combined secukinumab groups than in the etanercept group (7 patients [0.7 %] vs. 36 patients [11.1 %]).
Conclusions
At present, there are no comparative safety data between TNF-α inhibitors and IL-17 axis inhibitors except for two short-term clinical trials. TNF-α inhibitors have an advantage because of a well-defined safety profile based on more than a decade of use. However, based on the review of data from clinical trials, IL-17 axis inhibitors are equally safe. Rates of infection are comparable between the two groups, but risk of opportunistic infection particularly reactivation of TB is higher with TNF-α inhibitors.
Risk of malignancies with long-term use of biologics is still unclear. Based on observational data, malignancy risk other than NMSK has not been shown to be increased with the use of TNF-α inhibitors. With the short duration of availability, it is unclear if IL-17 axis inhibitors will reveal this same association. Based on current clinical trial data, risk of malignancy with IL-17 inhibitors is comparable to TNF-α inhibitors.
Higher rates of cardiovascular events have been noted in ustekinumab clinical trial data. However, increased rates of CV events have not been seen with secukinumab when used in clinical trials. Similarly, no increased CV events are seen with the TNF antagonist both from clinical trial and long-term registry data.
New-onset or worsening psoriatic plaques, particularly the plantar-palmarpustular type, have been reported with exposure to TNF inhibitors. This has not been seen with IL-17 or IL-12/23 inhibitors during the clinical trials, but there are few reports of pustular psoriasis with ustekinumab from post-marketing data. Both TNF-α inhibitors and IL-17 axis blockade agents have been noted to cause injection site erythema or local reactions; TNF-α inhibitors exhibited significantly more reactions than IL-17 axis inhibitors.
Uveitis usually improves with TNF blockers but paradoxically can worsen with the TNF-receptor blocker. At this time, there is no data noting the worsening of uveitis with any IL-17 axis blocker. There is a low risk of incident inflammatory bowel disease as well as exacerbation of prevalent inflammatory bowel disease with the anti-IL-17A monoclonal antibody. This has not been seen with TNF-α inhibitors except with etanercept.
In conclusion, there are very few discrepancies in adverse events of TNF blockade and IL-17 axis blockade therapies. Time-dependent differences in adverse events between the two classes of biologics may become evident. With longer-term and head-to-head studies, more clarity in understanding of the differential adverse effects may become obvious. However, one always needs to keep in mind the potential for complication like infections, malignancy, and cardiovascular and hematologic side effects when prescribing biologics.
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